See the DrugPatentWatch profile for Nplate
What were Nplate’s pivotal clinical trials used for?
Nplate (romiplostim) pivotal trials were designed to show that the drug could raise platelet counts in people with chronic immune thrombocytopenia (ITP) and reduce the need for other ITP treatments. The core pivotal program focused on patients whose platelet counts remained low despite prior therapy, with endpoints centered on achieving and maintaining platelet responses during treatment [1][2].
Which pivotal study looked at long-term response in chronic ITP?
A key pivotal study for chronic ITP evaluated whether romiplostim could provide sustained platelet count increases over repeated treatment cycles and assessed response durability across dosing periods [1]. The trial reporting supports the drug’s use for chronic ITP when patients have had an inadequate response to corticosteroids, immunoglobulins, or splenectomy [1].
How did the pivotal trials measure “response”?
Across the pivotal program, platelet response was measured using thresholds for platelet count achievement and maintenance, tracked over treatment time, rather than a one-time rise. The trials also monitored ongoing exposure and safety because increasing platelets must be balanced against treatment-related risks [1][2].
Who were the pivotal-trial participants (typical eligibility)?
Participants in the pivotal studies were adults with chronic immune thrombocytopenia and insufficient platelet responses to prior therapies. Enrollment generally focused on patients with persistently low platelet counts despite existing management strategies, matching the labeled population for chronic ITP treatment [1].
What outcomes did the pivotal trials support for approval?
The pivotal data supported that Nplate could increase platelet counts to reduce bleeding risk and improve platelet levels in chronic ITP patients. These findings were the basis for regulatory decisions covering dosing and clinical use in chronic ITP [1][2].
Where can I find the pivotal-trial details (protocols, endpoints, publications)?
Trial identifiers, endpoint descriptions, and results are summarized in secondary sources that compile pivotal study information for romiplostim/Nplate, including the prescribing information and detailed clinical overviews [1][2].
Sources
- https://www.drugs.com/clinical_trials/nplate-romiplostim.html
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4194212/